Table 1.

Patient characteristics

Patient	Sex/age (years)	Diagnosis/clinical stage	TSEBT dose	Concurrent therapy	Maintenance therapy	Acute toxicities D1–W6	Sub-acute toxicities W8–W12	Response	mSWAT reduction	PFS (W)	FU
1	M/69	SS	2 × 4 Gy	None	Bexarotene	Edema, erythema, and nail atrophy grade 2	Edema and alopecia grade 1	PR	88% at W8	26	Alive without evidence of progression
2	M/66	MF/IIB	2 × 4 Gy	None	Mogamulizumab	Sepsis, alopecia grade 1, and nausea grade 1	Nail changes and alopecia grade 1	PR	87% at W8	26	Died due to COVID-19
3	M/78	MF/IIB	2 × 4 Gy	Bexarotene	Bexarotene	Edema, erythema grade, alopecia, and blistering grade 1	Alopecia grade 1	PR	73% at W8	26	Alive without evidence of progression
4	F/77	SS	2 × 4 Gy	None	Bexarotene, ECP	Erythema grade 2, edema grade 2, alopecia grade 1	Fatigue, nail changes, and alopecia grade 1	PR	63% at W8	22	Alive without evidence of progression
5	M/60	MF/IIB	2 × 4 Gy	Bexarotene	Bexarotene	Erythema and fatigue grade 1	Fatigue, and edema grade 1	PR	89% at W8	19	Alive without evidence of progression
6	F/55	MF/IIB	2 × 4 Gy	Acitretin	Acitretin	Fatigue, erythema, and blistering grade 1	None	CR	100% at W4	18	Alive without evidence of disease

ECP extracorporeal photopheresis, CR complete response, W week, PR partial remission, PFS progression-free survival, FU follow-up, M male, F female, MF mycosis fungoides, SS Sézary syndrome